ASCO 2021 – Martin Reck
Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.
Here is the full ASCO 2021 report.
More posts
Early-stage lung cancer: immunotherapeutic standards
Despite established strategies such as platinum-based chemotherapy and EGFR-targeted agents, there is a high unmet need for improved adjuvant treatment in the setting of completely resected early-stage NSCLC (stage IB-IIIA). Therefore, the global phase III IMpower010 trial tested the anti-PD-L1 antibody atezolizumab 1,200 mg every 21 days for 16 cycles compared to best supportive care (BSC) in patients with stage IB-IIIA lung cancer who had undergone lobectomy or pneumonectomy followed by 1-4 cycles of chemotherapy.
Preface ASCO 2021
As in 2020, the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held online, with both the scientific and education programs taking place on June 4-8. Among more than 2,500 abstracts presented, findings in the area of lung cancer made for exiting news. Immune checkpoint inhibition has been moving forward in the continuum of care across the treatment lines and is now defining new standards in early-stage lung cancer.
